Old antibiotic could be a new weapon to fight tuberculosis

February 20, 2012
Old antibiotic could be a new weapon to fight TB

(Medical Xpress) -- A cheap and safe antibiotic that is widely available in the developing world might have a new use as a tuberculosis (TB) treatment, according to new research.

TB kills almost 2 million people a year worldwide, and is increasingly becoming resistant to the antibiotics used to treat it, but there are few new drugs in the pipeline. Doxycycline was introduced in 1967 and is used to treat a wide range of bacterial infections, but until now has not been recognized as effective against TB. The new study, published in the American Journal of Respiratory and , suggests that doxycycline might stop the bacteria from growing and also prevent the disease from damaging the lungs.

Last year, researchers at Imperial College London discovered that TB increases the production of an enzyme called MMP-1, and that this enzyme is responsible for destroying .

Now they have found that doxycycline suppresses the production of the tissue-destroying enzyme in TB-infected . They also found that doxycycline directly inhibits the growth of the bacteria in – a surprising result since the drug has been widely used as an antibiotic for over 40 years but has not been considered effective against TB.

has remained unchanged for over 30 years, and totally drug-resistant strains are emerging, so there’s a real need for .” said Dr. Paul Elkington, from the Department of Medicine at Imperial College London, who led the study. “Because doxycycline is cheap, safe and widely available throughout the developing world, it may be a useful new treatment for TB that can be used in resource-poor settings. Our results so far are promising but we have only looked at human cells and animal models. We hope to carry out a clinical trial soon to test whether doxycycline is effective at combating TB in patients.”

The researchers found further evidence for the antibiotic effect of doxycycline in TB bacteria grown in a liquid broth. The higher the concentration of , the lower the rate of bacterial growth.

They also studied HIV-infected TB patients in South Africa to look for further evidence that MMP-1 is responsible for destroying lung tissue. They found that concentrations of this enzyme were suppressed in people with advanced HIV infection, explaining for the first time why such patients do not suffer from such extensive lung destruction when they get TB.

The Imperial team worked with collaborators at the University of Cape Town and the Health Protection Agency (HPA) at Porton Down. The research was funded by the National Institute for Health Research (NIHR), the Wellcome Trust, the NIHR Biomedical Research Centre at Imperial, and the HPA.

Explore further: TB discovery paves the way for drugs that prevent lung destruction

More information: NF Walker et al. ‘Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.’ American Journal of Respiratory and Critical Care Medicine, published online 16 February 2012. , doi:10.1164/rccm.201110-1769OC

Related Stories

TB discovery paves the way for drugs that prevent lung destruction

April 25, 2011
Scientists have identified a key enzyme responsible for destroying lung tissue in tuberculosis (TB), they report today in the Journal of Clinical Investigation. Drugs that inhibit this enzyme are already available, meaning ...

Recommended for you

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet Feb 20, 2012
Bacteria use iron to survive and proliferate. Increased iron is known to increase infection. Many of the antibiotics work on that principle , removing iron.

"Doxycycline possesses iron-chelating activity"

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.